GARDP

Geneva, 26 April 2022 – A large study focusing on newborn babies with clinically diagnosed sepsis has revealed the impact of antibiotic resistance on neonatal sepsis, a major cause of death in newborns.

At the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), the Global Antibiotic Research and Development Partnership (GARDP) has released a second wave of findings from its study on the outcomes of more than 3,200 newborns with neonatal sepsis,

Ginevra, 26 Aprile 2022 – Un importante studio sui neonati ha rivelato l’impatto della resistenza agli antibiotici sulla sepsi neonatale, una delle principali cause di morte tra i neonati.

Al Congresso europeo di microbiologia clinica e malattie infettive (ECCMID), GARDP – un partenariato internazionale per la ricerca e lo sviluppo di antibiotici (Global Antibiotic Research and Development Partnership) – ha presentato una serie di risultati provenienti da uno studio condotto su oltre 3.200 neonati con sepsi neonatale,

We are delighted to see an article on children’s antibiotics, co-authored by GARDP R&D Director, Dr Seamus O’Brien, Penta’s Chief Scientific Officer, Prof. Theo Zakoutlis and Prof. Mike Sharland, from St. George’s, University of London, published in AMR Control, as governments have been discussing AMR at the World Health Assembly.

In R&D for children’s antibiotics: a wake-up call the authors explain how AMR has a disproportionate effect on children,

Penta have joined forces with GARDP (The Global Antibiotic Research & Development Partnership) to tackle drug-resistant infections in children. Our strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines.

Globally, more than three million childhood deaths result from infectious diseases,